Compare Impinj Inc (PI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Impinj Inc vs Zoetis Inc — how do they compare? Impinj Inc trades at $137.27 (market cap $4.14B), while Zoetis Inc trades at $74.43 (market cap $31.59B). The key difference: Zoetis Inc is far larger — about 7.6× Impinj Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Impinj Inc pays none. Which is the better fit depends on your goals.
| PI | ZTS | |
|---|---|---|
Market Cap | $4.14B | $31.59B |
Sector | Technology | Health |
52-Week High | $241.91 | $156.76 |
52-Week Low | $91.34 | $71.91 |
Enterprise Value | $4.28B | $38.89B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $137.72, down 0.33% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported mixed Q1 2026 results with $0.14 EPS beating expectations but faces profitability challenges with negative net income margins. Analyst sentiment remains strongly positive with 73% buy ratings and a $167.50 consensus price target, representing 22% upside potential from current levels.
While analyst optimism and RFID market positioning provide upside potential, significant risks include persistent negative profitability, high valuation multiples, and recent insider selling. The stock's technical weakness near key support levels at $136-$135 suggests near-term caution despite long-term growth prospects in the expanding RFID market.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
